×
MediWound Operating Expenses 2012-2024 | MDWD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
MediWound operating expenses from 2012 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
View More
MediWound Operating Expenses 2012-2024 | MDWD
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
MediWound operating expenses from 2012 to 2024. Operating expenses can be defined as the sum of all operating expenses for the given industry.
Related Stocks
Company Name
Market
Cap
Zoetis (ZTS)
$87.5B
Takeda Pharmaceutical (TAK)
$47.5B
Merck (MKGAF)
$24.4B
Astellas Pharma (ALPMY)
$22B
Sandoz Group AG (SDZNY)
$17.6B
Summit Therapeutics (SMMT)
$16.8B
United Therapeutics (UTHR)
$15.6B
Shionogi (SGIOY)
$13.3B
Neurocrine Biosciences (NBIX)
$12.2B
Catalent (CTLT)
$10.9B
Revolution Medicines (RVMD)
$7.7B
Orion OYJ (ORINY)
$7.4B
Jazz Pharmaceuticals (JAZZ)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.2B
Hikma Pharmaceuticals Plc (HKMPF)
$5.7B
Madrigal Pharmaceuticals (MDGL)
$5.3B
Crinetics Pharmaceuticals (CRNX)
$4.3B
Corcept Therapeutics (CORT)
$4.3B
Dyne Therapeutics (DYN)
$3.7B
PTC Therapeutics (PTCT)
$2.8B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$2.7B
Arrowhead Pharmaceuticals (ARWR)
$2.6B
Catalyst Pharmaceuticals (CPRX)
$2.5B
Soleno Therapeutics (SLNO)
$2B
Recursion Pharmaceuticals (RXRX)
$2B
Centessa Pharmaceuticals (CNTA)
$1.8B
BioCryst Pharmaceuticals (BCRX)
$1.7B
Xencor (XNCR)
$1.7B
Harrow (HROW)
$1.6B
Cassava Sciences (SAVA)
$1.5B